Insider · SEC Form 4 filer
Gary Pace
Past buys: 1 of 3 beat
Companies
Where they file as an insider
Cardiff Oncology (CRDF) Director Latest filing Jul 14, 2026
Pacira BioSciences (PCRX) Director Latest filing Mar 8, 2024
Track record
Did their buys beat the typical stock?
Open-market buys8
Quarters checked 6 months later3
Beat the typical stock 1 of 3
Quarters too new to check2
1 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Cardiff Oncology (CRDF) Bought Jul 14, 2026 · $1M · 687,285 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Cardiff Oncology (CRDF) Bought Jun 18, 2026 · $36.6K · 30,000 shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Cardiff Oncology (CRDF) Bought Jul 30, 2025 · $710K · 290,000 shares Behind typical Sep 30, 2025 $2.06 → Mar 31, 2026 $1.62 · −21.4% (typical stock −3.4%)
Cardiff Oncology (CRDF) Bought Dec 11, 2024 · $940K · 361,615 shares Behind typical Dec 31, 2024 $4.34 → Jun 30, 2025 $3.15 · −27.4% (typical stock −3.4%)
Cardiff Oncology (CRDF) Bought Nov 10–Dec 19, 2023 · $63.6K · 52,950 shares Beat typical Dec 31, 2023 $1.48 → Jun 30, 2024 $2.22 · +50.0% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.